Opioids offer little relief of chronic pain not due to cancer, according to a systematic review and meta-analysis. (JAMA)
Probiotics for bipolar disorder? A new study suggested the good bacteria might help improve mood by reducing gut inflammation. (ScienceDaily)
The FDA will review Intra-Cellular Therapies’ investigational schizophrenia treatment lumateperone — a dual 5HT2A receptor antagonist/dopamine phosphoprotein modulator.
People who weren’t always sure of their next meal were more likely to exhibit binge-eating behaviors. “This is an important study because it expands our view as to who might be susceptible to binge-eating disorder,” said study author Janet Lydecker, PhD, of the Yale School of Medicine, in a statement. (International Journal of Eating Disorders)
In people with opioid addiction, there weren’t any differences on comorbid anxiety, depression and insomnia with extended-release naltrexone (XR-NTX) compared with combined buprenorphine-naloxone. “Comorbid symptoms of anxiety, depression, or insomnia in abstinence-motivated persons with opioid dependence should not prevent switching from treatment with an opioid agonist to treatment with XR-NTX,” said the researchers in JAMA Psychiatry.
The investigational oral treatment for suicidal bipolar depression, NRX-101, helped reduce symptoms and was well-tolerated in the phase II STABIL-B study, said NeuroRx.
A group of Australian researchers reversed symptoms of dementia in mice with a novel ultrasound technique to remove amyloid plaques. (New Atlas)
Palo Alto Health Sciences’s digital therapeutic device Freespira was FDA-cleared for the treatment of PTSD.
Pear Therapeutics announced plans to begin testing its own digital therapeutic for schizophrenia.